Erectile Dysfunction &
Advanced Men’s Therapies
At Center for Men’s Health Rhode Island, we evaluate male sexual function as an integrated vascular, endocrine, structural, and neurogenic discipline—delivering guideline-concordant medical and non-surgical care in a private Providence setting.
Multi-System Diagnostics • Tiered Pharmacotherapy • Structural & Vascular Rehabilitation
Multi-System Diagnostic Workups
Erectile dysfunction (ED) is frequently an early clinical marker of systemic endothelial dysfunction, cardiometabolic shifts, androgen deficiency, or tunica albuginea remodeling. Generic, algorithmic prescriptions often fail because they overlook the underlying physiological mechanism.
In alignment with American Urological Association (AUA) Clinical Guidelines, our clinicians perform a structured medical, vascular, and endocrine evaluation—utilizing validated symptom indices alongside targeted laboratory testing—to match your presentation with the appropriate tier of care.
Regulatory Disclosure: Extracorporeal Shockwave Status
Low-intensity extracorporeal shockwave therapy (Li-ESWT / rESWT) is offered as a non-surgical acoustic pulse option for select vasculogenic ED and Peyronie’s presentations. Acoustic wave therapy is not FDA-cleared or FDA-approved for the treatment of erectile dysfunction, BPH, or Peyronie’s disease; per AUA and SMSNA position statements, its use for these indications is classified as investigational in the United States and is provided on a transparent self-pay basis.

Specialist-Led Vascular & Sexual Care
Because penile cavernous arteries measure only 1 to 2 millimeters in diameter, changes in erectile rigidity often precede broader cardiovascular or metabolic symptoms by several years. Every evaluation at our Providence clinic includes a comprehensive review of cardiovascular risk factors, medication interactions, and endocrine biomarkers.
Using shared clinical decision-making, our licensed clinicians guide you through evidence-based options in a welcoming, private environment.
Book Clinical ConsultationClinical Modality Spectrum
Comprehensive overview of pharmacological, mechanical, and acoustic modalities managed or coordinated at Center for Men’s Health Rhode Island.
| Modality Class | Therapeutic Agents / Systems | Physiological Mechanism | Primary Clinical Context |
|---|---|---|---|
| Oral PDE5 Inhibitors | FDA-Approved Phosphodiesterase Type 5 Inhibitors (Sildenafil, Tadalafil, Vardenafil, Avanafil) | Inhibits cGMP hydrolysis within corpus cavernosum smooth muscle, amplifying nitric oxide-mediated arterial inflow | First-line pharmacotherapy for mild-to-moderate vasculogenic or mixed ED |
| Intracavernosal Injections (ICI) | FDA-Approved Alprostadil or Patient-Specific Compounded Vasoactive Formulations (Bimix / Trimix) | Direct intracavernosal smooth muscle relaxation via prostaglandin E1, cyclic AMP, and alpha-adrenergic blockade | Moderate-to-severe organic ED, PDE5i non-responders, or post-prostatectomy nerve trauma |
| Endocrine Optimization | Guideline-Concordant Testosterone Therapy (TTh) | Restores physiological androgen receptor signaling, nitric oxide synthase expression, and central libido | ED co-occurring with biochemically confirmed male hypogonadism |
| Vacuum Erection Devices (VED) | Medical-Grade Negative-Pressure Cylinders & Tension Rings | Mechanically draws arterial and venous blood into the corpora cavernosa to support tissue oxygenation | Non-pharmacological erection assistance and post-surgical penile rehabilitation |
| Peyronie’s Conservative Care | Mechanical Penile Traction Therapy (PTT), Oral/Topical Support & Acoustic Modalities | Mechanotransduction and remodeling of tunica albuginea collagen fibers to address curvature and discomfort | Acute or stable phase Peyronie’s plaque and penile deformity |
| Acoustic Wave Therapy (Li-ESWT / rESWT) | Extracorporeal Acoustic Pressure Wave Systems | Mechanical shear stress investigated in clinical literature for local microvascular and tissue signaling | Investigational, non-surgical self-pay option for mild-to-moderate vasculogenic ED |
| Surgical Prosthetics Referral | Inflatable 3-Piece & Malleable Penile Prostheses (Surgical Urology Coordination) | Internal surgical placement of hydraulic or semi-rigid cylinders providing mechanical rigidity on demand | End-stage or refractory organic ED unresponsive to medical management |
Targeted Clinical Pathways
Individualized care plans progress systematically from foundational endothelial and endocrine support to advanced localized therapies.
Oral Pharmacotherapy & Endocrine Alignment
Individualized selection of oral PDE5 inhibitors tailored to pharmacokinetic half-life and patient routine, paired with comprehensive screening for concurrent nitrate contraindications and underlying androgen deficiency.
Intracavernosal Injection Therapy (ICI)
For men who do not achieve satisfactory response with oral agents, intracavernosal vasoactive therapy bypasses intact nerve signaling to produce direct arterial dilation—supported by in-office clinician education and priapism safety counseling.
Peyronie’s & Structural Remodeling
Phase-specific evaluation of acquired penile curvature and palpable tunica albuginea plaques, integrating non-surgical traction principles, symptom management, and urological surgical co-management when indicated.
Mechanical Rehabilitation & Acoustic Modalities
Deployment of medical-grade Vacuum Erection Devices (VEDs) for cavernous oxygenation and post-pelvic-surgery rehabilitation, alongside optional investigational acoustic wave support for eligible candidates.

Peyronie’s Disease & Curvature Evaluation
Peyronie’s disease is an acquired connective tissue disorder of the penile tunica albuginea characterized by localized fibrous collagen plaques, penile angulation, indentation, pain during erection, and frequently co-occurring erectile dysfunction.
In accordance with the AUA Peyronie’s Disease Clinical Guideline, early clinical assessment is critical to differentiate the acute active inflammatory phase from the chronic stable fibrotic phase, guiding appropriate conservative vs. interventional care.
Schedule Structural AssessmentInsurance & Self-Pay Pathways
Transparent billing without high-pressure multi-cycle contracts for diagnostic workups and specialized therapies.
Clinical Evaluations & Diagnostics
Initial medical consultations, vascular/urological assessments, and diagnostic endocrine blood panels frequently utilize commercial health insurance. Our team assists with benefit verification prior to your visit.
Specialty Compounded Rx, VEDs & Acoustic Care
Patient-specific compounded ICI medications, medical-grade VED systems, conservative Peyronie’s care, and investigational acoustic wave sessions are offered with transparent self-pay pricing.
Clinical Guidelines & Statutory Disclosures
Our diagnostic protocols and patient disclosures are grounded in peer-reviewed urological guidelines and federal regulatory standards.
Primary Urological Guidelines & Regulatory Sources
- American Urological Association (AUA) — Erectile Dysfunction: Burnett AL, Nehra A, Breau RH, et al. Erectile Dysfunction: AUA Guideline. Journal of Urology. View AUA Erectile Dysfunction Guideline ↗
- American Urological Association (AUA) — Peyronie’s Disease: Nehra A, Alterowitz R, Culkin DJ, et al. Peyronie’s Disease: AUA Guideline. Journal of Urology. View AUA Peyronie’s Disease Guideline ↗
- Sexual Medicine Society of North America (SMSNA): Position statements on restorative therapies, shockwave modalities, and evidence-based management of male sexual dysfunction. Visit Sexual Medicine Society of North America (SMSNA) ↗
- U.S. Food & Drug Administration (FDA) — Section 503A Compounding & PDE5i Labeling: Federal oversight regarding prescription phosphodiesterase type 5 inhibitors (contraindicated with organic nitrates) and human drug compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act. View FDA Section 503A Compounding Provisions ↗
Medical & Emergency Safety Disclaimer: Website content is provided strictly for educational and informational purposes and does not constitute medical advice, clinical diagnosis, or treatment. Oral PDE5 inhibitors are strictly contraindicated in patients taking organic nitrates or guanylate cyclase stimulators due to the risk of life-threatening hypotension. Intracavernosal injection (ICI) therapies carry a clinical risk of prolonged erection or priapism (an erection lasting greater than 4 hours), penile pain, or corporeal fibrosis; any erection lasting more than 4 hours requires immediate emergency medical evaluation to prevent permanent tissue damage.
Compounding & Investigational Modality Disclosure: Patient-specific compounded medications (such as Bimix or Trimix) are prepared by independently licensed 503A compounding pharmacies pursuant to a valid patient-specific prescription; compounded preparations are not FDA-approved, and the FDA does not verify the safety, effectiveness, or quality of compounded drugs prior to marketing. Low-intensity shockwave therapy (Li-ESWT / rESWT) is not FDA-approved or FDA-cleared for erectile dysfunction or Peyronie’s disease. Review our full Clinical Transparency & Pharmacy Disclosures and Terms of Service.
